A double-blind, placebo-controlled, randomized, 18-month Phase 2a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral UCB0599 in study participants with early Parkinson’s Disease
Lay Description
Category
- Nervous System
- IRB Number
- 20200883HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Sarah Horn
(210) 450-0501
horns@uthscsa.edu
Sarah Martinez
(210) 450-0569
martinezs23@uthscsa.edu
Charlotte Rhodes
(210) 450-8454
rhodesc1@uthscsa.edu
Charlotte Rhodes
(210) 450-8454
rhodesc1@uthscsa.edu
Principal Investigator
Sarah Horn